AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17634485 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (DOX)
Number of subjects: 445
Study 16436239 — intervention group
Group type: EXPERIMENTAL
Intervention: Méniètt device (local overpressure treatment)
Number of subjects: 0
Study 16436239 — intervention group
Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 0
Study 14761073 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (8‐12 mg once a day)
Number of subjects: 100
Study 14761073 — intervention group
Group type: COMPARATOR
Intervention: Dihydropyridine calcium-channel blockers (DCCBs)
Number of subjects: 100
Study 10872643 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone 50 mg
Number of subjects: 412
Study 10872643 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone 200 mg
Number of subjects: 412
Study 10872643 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone 400 mg
Number of subjects: 412
Study 10872643 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 412
Study 10872643 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone (various doses)
Number of subjects: 412
Study 10872643 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone
Number of subjects: 412
Study 9031808 — intervention group
Group type: EXPERIMENTAL
Intervention: PDPD patients
Number of subjects: 110
Study 9031808 — intervention group
Group type: COMPARATOR
Intervention: Type 1 diabetes patients
Number of subjects: 110
Study 9031808 — intervention group
Group type: EXPERIMENTAL
Intervention: PDPD patients at onset
Number of subjects: 110
Study 9031808 — intervention group
Group type: COMPARATOR
Intervention: FCPD patients
Number of subjects: 110
Study 1984381 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg morphine
Number of subjects: 154
Study 1984381 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg morphine
Number of subjects: 154
Study 1984381 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 154
Study 1984381 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (2 mg, 4 mg, placebo)
Number of subjects: 154
Study 6138061 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of midazolam
Number of subjects: 0
Study 6138061 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of midazolam
Number of subjects: 0
Study 6138061 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of midazolam
Number of subjects: 0
Study 6138061 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of flurazepam
Number of subjects: 0
Study 6138061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31189985 — intervention group
Group type: EXPERIMENTAL
Intervention: High definition TACS
Number of subjects: 60
Study 31189985 — intervention group
Group type: COMPARATOR
Intervention: High definition TDCS
Number of subjects: 60
Study 31189985 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 60
Study 29863387 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg of tiagabine/day
Number of subjects: 12
Study 29863387 — intervention group
Group type: COMPARATOR
Intervention: 0 mg of tiagabine/day (placebo)
Number of subjects: 12
Study 27053573 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietetic weight loss intervention (at least four sessions with an Accredited Practising Dietitian)
Number of subjects: 40
Study 27053573 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study 27053573 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietetic weight loss intervention
Number of subjects: 40
Study 24665641 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous operation
Number of subjects: 50
Study 24665641 — intervention group
Group type: COMPARATOR
Intervention: Staging operation
Number of subjects: 50
Study 22299805 — intervention group
Group type: EXPERIMENTAL
Intervention: Prize-based contingency management (CM) intervention contingent on submitting negative urine drug screens (UDS)
Number of subjects: 31
Study 22299805 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent control group
Number of subjects: 31
Study 19185539 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (exact dosage and duration not specified)
Number of subjects: 1493
Study 17397610 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium heparin 100 IU (study 1)
Number of subjects: 223
Study 17397610 — intervention group
Group type: COMPARATOR
Intervention: Sodium heparin 500 IU (control 1)
Number of subjects: 223
Study 17397610 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline solution (SS) (study 2)
Number of subjects: 223
Study 17397610 — intervention group
Group type: COMPARATOR
Intervention: Sodium heparin 100 IU (control 2)
Number of subjects: 223
Study 15792677 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg atorvastatin
Number of subjects: 30
Study 15792677 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin
Number of subjects: 30
Study 15792677 — intervention group
Group type: COMPARATOR
Intervention: none (control)
Number of subjects: 30
Study 12147166 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% NaF mouthrinse for 2 years
Number of subjects: 0
Study 12147166 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% NaF mouthrinse
Number of subjects: 0
Study 12147166 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fluoride program)
Number of subjects: 0
Study 12147166 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF content reduction
Number of subjects: 0
Study 10519944 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg of MSP-1(19) vaccine
Number of subjects: 16
Study 10519944 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg of MSP-1(19) vaccine
Number of subjects: 16
Study 10519944 — intervention group
Group type: COMPARATOR
Intervention: Control vaccines (hepatitis B or Td)
Number of subjects: 16
Study 8573550 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (PRAV)
Number of subjects: 32
Study 8573550 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (LOV)
Number of subjects: 32
Study 8573550 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine (CHOL)
Number of subjects: 32
Study 8573550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 2209838 — intervention group
Group type: EXPERIMENTAL
Intervention: Early second surgery after three cycles of cis-platinum-based chemotherapy (median of 14 weeks from initial laparotomy)
Number of subjects: 24
Study 2209838 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical series of patients with residual disease receiving cis-platinum but no early secondary surgery)
Number of subjects: 24
Study 7202896 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol up to 200 mg bid
Number of subjects: 119
Study 7202896 — intervention group
Group type: COMPARATOR
Intervention: methyldopa up to 500 mg bid
Number of subjects: 119
Study 7202896 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol alone after methyldopa
Number of subjects: 119
Study 31740343 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate (150 mg/month)
Number of subjects: 165
Study 31740343 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (70 mg/week)
Number of subjects: 165
Study 31740343 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (35 mg/week)
Number of subjects: 165
Study 31740343 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D (daily)
Number of subjects: 165
Study 31740343 — intervention group
Group type: COMPARATOR
Intervention: Control group (226 healthy premenopausal women receiving no treatments)
Number of subjects: 165
Study 31310626 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session pattern scanning laser (Pascal)
Number of subjects: 30
Study 31310626 — intervention group
Group type: COMPARATOR
Intervention: Conventional multiple-session laser
Number of subjects: 30
Study 27611235 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy-Enhanced (CBT-E)
Number of subjects: 80
Study 27611235 — intervention group
Group type: COMPARATOR
Intervention: Integrative Cognitive-Affective Therapy for BN (ICAT-BN)
Number of subjects: 80
Study 27611235 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality subtype
Number of subjects: 80
Study 23963625 — intervention group
Group type: EXPERIMENTAL
Intervention: school-based nutrition and physical activity curriculum
Number of subjects: 600
Study 23963625 — intervention group
Group type: EXPERIMENTAL
Intervention: across-the-lifespan train-the-trainer program
Number of subjects: 600
Study 23565841 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flavanol chocolate (40g dose)
Number of subjects: 44
Study 23565841 — intervention group
Group type: COMPARATOR
Intervention: Low-flavanol chocolate (40g dose)
Number of subjects: 44
Study 23565841 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flavanol chocolate (20g daily intake for 12 weeks)
Number of subjects: 44
Study 23565841 — intervention group
Group type: COMPARATOR
Intervention: Low-flavanol chocolate (20g daily intake for 12 weeks)
Number of subjects: 44
Study 21150222 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis treatment
Number of subjects: 8963
Study 21150222 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident patients
Number of subjects: 8963
Study 21150222 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalent patients
Number of subjects: 8963
Study 21150222 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication use
Number of subjects: 8963
Study 21150222 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal transplantation
Number of subjects: 8963
Study 19208728 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin analogs (SSA) treatment
Number of subjects: 31
Study 17854530 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of cervical mucus prior to embryo transfer
Number of subjects: 317
Study 17854530 — intervention group
Group type: COMPARATOR
Intervention: Mock procedure (control)
Number of subjects: 317
Study 15494100 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg E(2)V + 2.5 mg MPA
Number of subjects: 419
Study 15494100 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg E(2)V + 5 mg MPA
Number of subjects: 419
Study 15494100 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg E(2)V + 2.5 mg MPA
Number of subjects: 419
Study 15494100 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg E(2)V + 5 mg MPA
Number of subjects: 419
Study 11806199 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy (intravenous and supravenous)
Number of subjects: 173
Study 11806199 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy
Number of subjects: 173
Study 11806199 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no laser radiation)
Number of subjects: 173
Study 10193280 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ketamine 10 mg i.v. bolus followed by 10 mg h‐1 infusion for 48 h
Number of subjects: 60
Study 10193280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8164327 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 infusion at a rate of 30 ng.kg‐1 x min‐1 during surgery and 10‐30 ng.kg‐1 x min‐1 after surgery
Number of subjects: 12
Study 8164327 — intervention group
Group type: COMPARATOR
Intervention: No PGE1 infusion (control group)
Number of subjects: 12
Study 3284285 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy with mechanical ventilation (Group B)
Number of subjects: 69
Study 3284285 — intervention group
Group type: COMPARATOR
Intervention: Oxygen therapy only (Group A)
Number of subjects: 69
Study 29690729 — intervention group
Group type: EXPERIMENTAL
Intervention: NEO‐GAIT
Number of subjects: 60
Study 29690729 — intervention group
Group type: COMPARATOR
Intervention: CPM
Number of subjects: 60
Study 27130908 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13 (3 mg/kg) administered intravenously every 8 weeks from weeks 62 to 102, with concomitant methotrexate.
Number of subjects: 302
Study 27130908 — intervention group
Group type: COMPARATOR
Intervention: RP (Remicade) for 54 weeks followed by CT-P13 (3 mg/kg) administered intravenously every 8 weeks from weeks 62 to 102, with concomitant methotrexate.
Number of subjects: 302
Study 26206177 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal
Number of subjects: 32
Study 26206177 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic
Number of subjects: 32
Study 26206177 — intervention group
Group type: EXPERIMENTAL
Intervention: Supreme
Number of subjects: 32
Study 26206177 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 32
Study 26206177 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube (LT)
Number of subjects: 32
Study 26206177 — intervention group
Group type: EXPERIMENTAL
Intervention: air-Q
Number of subjects: 32
Study 26206177 — intervention group
Group type: COMPARATOR
Intervention: All SGDs
Number of subjects: 32
Study 26206177 — intervention group
Group type: COMPARATOR
Intervention: ProSeal and Classic
Number of subjects: 32
Study 24282495 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint Crisis Plans (JCP) plus treatment as usual (TAU)
Number of subjects: 0
Study 24282495 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 24282495 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint Crisis Plans (JCP)
Number of subjects: 0
Study 21955538 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke volume guided intra‐operative fluid management using LiDCOplus with maintenance fluid and 250 ml colloid boluses to achieve sustained 10% increases in stroke volume
Number of subjects: 128
Study 21955538 — intervention group
Group type: COMPARATOR
Intervention: Fluid administration at the responsible (blinded) anaesthetist's discretion
Number of subjects: 128
Study 21955538 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke volume guided intra‐operative fluid management
Number of subjects: 128
Study 18981885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical arthroplasty (Prestige ST and Bryan)
Number of subjects: 93
Study 18981885 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion
Number of subjects: 93
Study 16534549 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day) continued for 6 weeks in group A
Number of subjects: 40
Study 16534549 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin withdrawn in group B
Number of subjects: 40
Study 16534549 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin started in groups C and D for 6 weeks
Number of subjects: 40
Study 16534549 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin withdrawn in group C after 6 weeks
Number of subjects: 40
Study 16534549 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin continued in group D after 6 weeks
Number of subjects: 40
Study 12669756 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustically salient prime
Number of subjects: 0
Study 12669756 — intervention group
Group type: EXPERIMENTAL
Intervention: Less salient prime
Number of subjects: 0
Study 14559927 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times daily for 21 days
Number of subjects: 32
Study 14559927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 10468218 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA treatment in PD patients
Number of subjects: 0
Study 10468218 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects and untreated PD patients)
Number of subjects: 0
Study 7644905 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia
Number of subjects: 100
Study 7644905 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid cardioplegia
Number of subjects: 100
Study 2670950 — intervention group
Group type: EXPERIMENTAL
Intervention: AO dynamic hip-screw
Number of subjects: 0
Study 2670950 — intervention group
Group type: COMPARATOR
Intervention: Traction
Number of subjects: 0
Study 2670950 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 0
Study 984277 — intervention group
Group type: EXPERIMENTAL
Intervention: Scrub Method
Number of subjects: 311
Study 984277 — intervention group
Group type: EXPERIMENTAL
Intervention: Scrub-Floss Method
Number of subjects: 311
Study 984277 — intervention group
Group type: EXPERIMENTAL
Intervention: Bass Method
Number of subjects: 311
Study 984277 — intervention group
Group type: EXPERIMENTAL
Intervention: Bass-Floss Method
Number of subjects: 311
Study 984277 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no supervised instructions)
Number of subjects: 311
Study 28885111 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 60
Study 28885111 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 60
Study 28885111 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral tDCS
Number of subjects: 60
Study 28885111 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 60
Study 25853905 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mg intraventricular TPA every 12 hours
Number of subjects: 12
Study 25853905 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 12 hours
Number of subjects: 12
Study 24012128 — intervention group
Group type: COMPARATOR
Intervention: Oral antibiotic treatment (group 1)
Number of subjects: 90
Study 24012128 — intervention group
Group type: EXPERIMENTAL
Intervention: Local antibiotic treatment (group 2)
Number of subjects: 90
Study 21835135 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (0.55, 2.5, or 10 mg/kg) administered every 4 weeks for a total of 3 infusions
Number of subjects: 59
Study 19558371 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Symptoms Checklist‐Revised (DSC‐R)
Number of subjects: 4000
Study 17942818 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg IV
Number of subjects: 205
Study 17942818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 17942818 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg IV (subgroup with migraine lasting longer than 72 hours)
Number of subjects: 205
Study 17942818 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subgroup with migraine lasting longer than 72 hours)
Number of subjects: 205
Study 15083429 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Functional Rehabilitation (IFR)
Number of subjects: 77
Study 15083429 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (Control)
Number of subjects: 77
Study 11490806 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional targeting chemoimmunotherapy (Group A, n = 44 patients)
Number of subjects: 86
Study 11490806 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemoimmunotherapy (Group B, n = 42 patients)
Number of subjects: 86
Study 9506650 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone lactate (50 microg/kg loading dose, then 0.5 microg/kg/min infusion)
Number of subjects: 20
Study 9506650 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone lactate (after discontinuation of infusion)
Number of subjects: 20
Study 9506650 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone lactate (during infusion)
Number of subjects: 20
Study 7635035 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human growth hormone (GH)
Number of subjects: 0
Study 3051628 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchiectomy plus combined hormone and chemotherapy (ethinylestradiol sulfonate plus vincristine/vinblastine, cyclophosphamide, methotrexate)
Number of subjects: 0
Study 3051628 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy plus antigonadotropic therapy alone (ethinylestradiol sulfonate)
Number of subjects: 0
Study 3051628 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy plus chemotherapy (vincristine/vinblastine, cyclophosphamide, methotrexate)
Number of subjects: 0
Study 31006879 — intervention group
Group type: EXPERIMENTAL
Intervention: Early nutrition within 48 hours after ICU admission (E+ group)
Number of subjects: 203
Study 31006879 — intervention group
Group type: COMPARATOR
Intervention: Delayed nutrition or no nutrition (E- group)
Number of subjects: 203
Study 31006879 — intervention group
Group type: EXPERIMENTAL
Intervention: Early nutrition (E+ group)
Number of subjects: 203
Study 31136113 — intervention group
Group type: EXPERIMENTAL
Intervention: mirabegron 50mg
Number of subjects: 62
Study 31136113 — intervention group
Group type: COMPARATOR
Intervention: solifenacin 5mg
Number of subjects: 62
Study 28973318 — intervention group
Group type: EXPERIMENTAL
Intervention: IOL repositioning by scleral suturing 1.5- to 2-mm posterior to limbus
Number of subjects: 104
Study 28973318 — intervention group
Group type: COMPARATOR
Intervention: IOL exchange with a retropupillar iris-claw IOL using a 5.5-mm scleral pocket incision
Number of subjects: 104
Study 26377161 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quintile of serum retinol (s-retinol)
Number of subjects: 21774
Study 26377161 — intervention group
Group type: COMPARATOR
Intervention: Middle quintile of serum retinol (s-retinol)
Number of subjects: 21774
Study 26377161 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper quintile of serum retinol (s-retinol)
Number of subjects: 21774
Study 26377161 — intervention group
Group type: EXPERIMENTAL
Intervention: Low retinol concentrations
Number of subjects: 21774
Study 26377161 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum concentrations of 25-hydroxyvitamin D
Number of subjects: 21774
Study 23388005 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine bathing (2% chlorhexidine-impregnated washcloths)
Number of subjects: 7727
Study 23388005 — intervention group
Group type: COMPARATOR
Intervention: Nonantimicrobial washcloths
Number of subjects: 7727
Study 21198560 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 80mg IV bolus
Number of subjects: 59
Study 21198560 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 59
Study 20042080 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 measure of diversity in meta-analysis
Number of subjects: 0
Study 20042080 — intervention group
Group type: COMPARATOR
Intervention: I2 measure of inconsistency in meta-analysis
Number of subjects: 0
Study 17090809 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity physical activity counseling
Number of subjects: 165
Study 17090809 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care
Number of subjects: 165